News and press releases

* (R) = Regulatory press releases

19 Mar, 2021

(R) Cantargia reports positive preclinical safety and efficacy results in the CAN10 project

10 Mar, 2021

(R) Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can

01 Mar, 2021

Cantargia provides business updates at investor conferences during March 2021

25 Feb, 2021

(R) Cantargia publishes full year report for 2020

17 Feb, 2021

Invitation to presentation of Cantargia’s Full Year Report for the period January – December 2020 on February 25 at 2.00 p.m. CET

10 Feb, 2021

(R) Cantargia reports first patient treated in CANFOUR pancreatic cancer phase IIa extension cohort

30 Dec, 2020

(R) New number of shares and votes in Cantargia

21 Dec, 2020

(R) Changes to Cantargia’s nomination committee

16 Dec, 2020

(R) Cantargia has completed a directed share issue of approximately SEK 564 million

15 Dec, 2020

(R) Cantargia announces intention of a directed share issue

Older press releases >>

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

Pareto Securities

CEO interview, Edison - 2021-03-15

Edison

CEO interview, Redeye, (In Swedish) - 2021-03-09

Redeye

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

Aktiespararna

CEO interview, Edison Open House - 2021-01-26

Edison

CEO interview, direct share issue, Redeye (In Swedish) - 2020-12-16

Redeye

CEO interview, direct share issue, Di TV (In Swedish) - 2020-12-16

Di TV

CEO interview, EFN (In Swedish) - 2020-10-16

EFN

CEO interview, Penser Bank Cancer Research Day (In Swedish) - 2020-10-07

Penser Bank

Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31

Affärstidningen Näringsliv

Presentation at ASCO 2019, follow up articles and interviews - 2019-07-02

ASCO

Cantargia interview at EFN after ASCO - 2019-06-17

EFN

CEO interview, Edison, London - 2019-02-26

Edison TV

CEO interview, EFN, Lund (In Swedish) - 2018-11-22

EFN

Interview around CAN04 clinical results, Redeye, Stockholm (In Swedish) - 2018-10-23

Redeye

Listing ceremony for Cantargia on Nasdaq Stockholm Main Market - 2018-09-25

Nasdaq

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), EFN, Stockholm (In Swedish) - 2018-09-25

EFN

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), Ditv, Stockholm (In Swedish) - 2018-09-25

CEO interview, Redeye, Stockholm (In Swedish) 2018-09-06

Redeye

CEO interview, BioStock Live, Stockholm (In Swedish) -2018-08-29

Direkt Studios

Småbolagspanelen: Om framtidens cancerbehandlingar, Småbolagsdagen, Stockholm (in Swedish) 2018-06-11

Aktiespararna

CEO interview BioStock Live, Stockholm (In Swedish) -2018-03-20

Direkt Studios

CEO-interview 2017-12-12

Aktiespararna

Interview with Cantargia's CEO Göran Forsberg after the presentation at BioStock Live i Stockholm - 2017-12-04

Direkt Studios

CEO-interview - 2017-11-29

Finwire.tv

Video, interview Göran Forsberg, President Cantargia, Sedermera-dagen, Lund - 2016-03-16

Finwire.tv

Press releases

(R) Cantargia reports positive preclinical safety and efficacy results in the CAN10 project

(R) Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can

Cantargia provides business updates at investor conferences during March 2021

(R) Cantargia publishes full year report for 2020

Invitation to presentation of Cantargia’s Full Year Report for the period January – December 2020 on February 25 at 2.00 p.m. CET

(R) Cantargia reports first patient treated in CANFOUR pancreatic cancer phase IIa extension cohort

(R) New number of shares and votes in Cantargia

(R) Changes to Cantargia’s nomination committee

(R) Cantargia has completed a directed share issue of approximately SEK 564 million

(R) Cantargia announces intention of a directed share issue

In media

Interview with CEO Göran Forsberg and CMO Ignacio Garcia-Ribas, Pareto - 2021-03-26

CEO interview, Edison - 2021-03-15

CEO interview, Redeye, (In Swedish) - 2021-03-09

Cantargia in a panel discussion on how to build a successful biotech company (In Swedish) - 2021-01-27

CEO interview, Edison Open House - 2021-01-26

CEO interview, direct share issue, Redeye (In Swedish) - 2020-12-16

CEO interview, direct share issue, Di TV (In Swedish) - 2020-12-16

CEO interview, EFN (In Swedish) - 2020-10-16

CEO interview, Penser Bank Cancer Research Day (In Swedish) - 2020-10-07

Article about Cantargias antibody based cancer treatment with multiple functions 2019-10-31

Presentation at ASCO 2019, follow up articles and interviews - 2019-07-02

Cantargia interview at EFN after ASCO - 2019-06-17

CEO interview, Edison, London - 2019-02-26

CEO interview, EFN, Lund (In Swedish) - 2018-11-22

Interview around CAN04 clinical results, Redeye, Stockholm (In Swedish) - 2018-10-23

Listing ceremony for Cantargia on Nasdaq Stockholm Main Market - 2018-09-25

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), EFN, Stockholm (In Swedish) - 2018-09-25

CEO interview in connection with listing Nasdaq Stockholm (Small Cap), Ditv, Stockholm (In Swedish) - 2018-09-25

CEO interview, Redeye, Stockholm (In Swedish) 2018-09-06

CEO interview, BioStock Live, Stockholm (In Swedish) -2018-08-29

Småbolagspanelen: Om framtidens cancerbehandlingar, Småbolagsdagen, Stockholm (in Swedish) 2018-06-11

CEO interview BioStock Live, Stockholm (In Swedish) -2018-03-20

CEO-interview 2017-12-12

Interview with Cantargia's CEO Göran Forsberg after the presentation at BioStock Live i Stockholm - 2017-12-04

CEO-interview - 2017-11-29

Video, interview Göran Forsberg, President Cantargia, Sedermera-dagen, Lund - 2016-03-16